Hepatic fibrosis is a common pathological process in chronic liver diseases, characterized
by excessive reactive oxygen species (ROS), activated hepatic stellate cells (HSCs), and …

Liver fibrosis is a pathological process of multiple chronic liver diseases progressing to
cirrhosis for which there are currently no effective treatment options. During fibrosis …

As hepatic stellate cells (HSCs) are essential for hepatic fibrogenesis, HSCs targeted nano-
drug delivery system is a research hotspot in liver fibrosis therapy. However, the excessive …

Hepatic stellate cell (HSC)-targeted delivery is an attractive strategy for liver fibrosis therapy,
but the efficacy is hampered by poor delivery of nanomaterials and complicated …

Liver fibrosis is featured by activation of hepatic stellate cells (HSCs) and excessive
accumulation of extracellular matrix (ECM). The Golgi apparatus in HSCs plays a vital role in …

Although direct hepatic stellate cell (HSC) inhibition is considered a promising strategy for
alleviating liver fibrosis, traditional therapies struggle with off‐target effects due to limited …

During liver fibrogenesis, liver sinusoidal capillarization and extracellular matrix (ECM)
deposition construct dual pathological barriers to drug delivery. Upon capillarization, the …

Liver fibrosis is characterized by excess reactive oxygen species (ROS) production, hepatic
stellate cell (HSC) activation, and subsequent extracellular matrix deposition. Since complex …

Hepatic fibrosis, characterized by excessive reactive oxygen species (ROS) generation,
hepatic stellate cells (HSCs) activation, and enormous extracellular matrix (ECM) …

Hepatic stellate cells (HSCs) exist in the liver's perisinusoidal space, are phenotypically
activated, and acquire myofibroblast‐like phenotype. This phenotypic transformation is …